Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 2/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | KRAS | P01116 | 9/20 | 0.36 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.36 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24499339 | 1.00 | STING1 (0.46) | STING1NT5EFUT5POLBTGM2 | |
| SCHEMBL21539236 | 0.92 | STING1 (0.46) | STING1NT5EFUT5POLBTGM2 | |
| SCHEMBL21943897 | 0.91 | STING1 (0.49) | STING1NT5EFUT5POLBTGM2 | |
| SCHEMBL24499584 | 0.91 | STING1 (0.49) | STING1NT5EFUT5POLBTGM2 | |
| SCHEMBL18521112 | 0.91 | STING1 (0.49) | STING1NT5EFUT5POLBTGM2 | |
| SCHEMBL18521199 | 0.91 | STING1 (0.49) | STING1NT5EFUT5POLBTGM2 | |
| SCHEMBL22381986 | 0.89 | STING1 (0.44) | STING1NT5EFUT5POLBTGM2 | |
| SCHEMBL18522079 | 0.87 | STING1 (0.48) | STING1NT5EFUT5POLBTGM2 | |
| SCHEMBL22381710 | 0.86 | STING1 (0.48) | STING1NT5EFUT5POLBTGM2 | |
| SCHEMBL18520949 | 0.86 | STING1 (0.48) | STING1NT5EFUT5POLBTGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220175811-A1 | STABLE FORMULATIONS OF CYCLIC DINUCLEOTIDE STING AGONIST COMPOUNDS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. (US) | 2022-06-09 | — | — | US | disclosed |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | STING1 1/4885NT5E 1372/4885FUT5 4404/4885 |
| US-20220175811-A1 | STABLE FORMULATIONS OF CYCLIC DINUCLEOTIDE STING AGONIST COMPOUNDS AND METHODS OF USE THEREOF | STING1, CGAS, IRF3 | STING1 1/4885NT5E 56/4885FUT5 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.